Richmond, Va.-based pharmaceutical manufacturing company Phlow will lead a team comprised of Civica Rx, Ampac Fine Chemicals and the Virginia Commonwealth University’s Medicines for All Institute to produce critical medicines for COVID-19 response through a potential 10-year, $812M contract from the Biomedical Advanced Research and Development Authority.
The team will develop chemical compounds for active pharmaceutical ingredients in an effort to help the government avoid or address drug shortages amid the coronavirus pandemic, the Department of Health and Human Services said Tuesday.
According to HHS, the alliance will apply advanced manufacturing systems and transfer a novel continuous production technology to designated businesses or other entities.
The Phlow-led group will initially receive $354M over four years as part of the agreement with BARDA and may extend work under the contract to provide system and supplies maintenance support.
“Utilizing advanced manufacturing processes increases the speed we can provide patients with treatments, reduces the likelihood of drug shortages and increases U.S. readiness," said Gary Disbrow, acting director of BARDA.
